Lexaria Bioscience Net Profit Margin Growth & History (LEXX)
Lexaria Bioscience's net profit margin was −1,686.00% for fiscal 2025.
View full Lexaria Bioscience company overviewLexaria Bioscience annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-08-31 | −1,686.00% | −437.75 pp |
| 2024 | 2024-08-31 | −1,248.25% | +6467.54 pp |
| 2023 | 2023-08-31 | −7,715.79% | −4869.51 pp |
| 2022 | 2022-08-31 | −2,846.28% | −2289.10 pp |
| 2021 | 2021-08-31 | −557.19% | +505.01 pp |
| 2020 | 2020-08-31 | −1,062.20% | +805.83 pp |
| 2019 | 2019-08-31 | −1,868.03% | −342.67 pp |
| 2018 | 2018-08-31 | −1,525.36% | +1506.53 pp |
| 2017 | 2017-08-31 | −3,031.89% | +104.93 pp |
| 2016 | 2016-08-31 | −3,136.82% | +10352.98 pp |
| 2015 | 2015-08-31 | −13,489.80% | — |
Lexaria Bioscience quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-02-28 | −7,249.89% | −5690.58 pp |
| Q4 2025 | 2025-08-31 | −1,549.33% | +1051.61 pp |
| Q3 2025 | 2025-05-31 | −2,177.64% | −56.58 pp |
| Q2 2025 | 2025-02-28 | −1,559.32% | −1111.36 pp |
| Q1 2025 | 2024-11-30 | −1,470.02% | −690.44 pp |
| Q4 2024 | 2024-08-31 | −2,600.94% | — |
| Q3 2024 | 2024-05-31 | −2,121.06% | +930.79 pp |
| Q2 2024 | 2024-02-29 | −447.96% | +6034.59 pp |
| Q1 2024 | 2023-11-30 | −779.57% | +1017.06 pp |
| Q3 2023 | 2023-05-31 | −3,051.86% | −662.17 pp |
| Q2 2023 | 2023-02-28 | −6,482.55% | −1830.75 pp |
| Q1 2023 | 2022-11-30 | −1,796.64% | +12563.28 pp |
| Q4 2022 | 2022-08-31 | −1,320.26% | +2477.47 pp |
| Q3 2022 | 2022-05-31 | −2,389.69% | −1131.91 pp |
| Q2 2022 | 2022-02-28 | −4,651.80% | −4856.58 pp |
| Q1 2022 | 2021-11-30 | −14,359.92% | −14119.74 pp |
| Q4 2021 | 2021-08-31 | −3,797.72% | −3559.59 pp |
| Q3 2021 | 2021-05-31 | −1,257.77% | +2560.29 pp |
| Q2 2021 | 2021-02-28 | 204.78% | +2861.29 pp |
| Q1 2021 | 2020-11-30 | −240.18% | +8710.28 pp |
| Q4 2020 | 2020-08-31 | −238.13% | +653.79 pp |
| Q3 2020 | 2020-05-31 | −3,818.06% | −1835.89 pp |
| Q2 2020 | 2020-02-29 | −2,656.51% | +4856.11 pp |
| Q1 2020 | 2019-11-30 | −8,950.46% | −5792.33 pp |
| Q4 2019 | 2019-08-31 | −891.92% | +381.70 pp |
| Q3 2019 | 2019-05-31 | −1,982.17% | +458.27 pp |
| Q2 2019 | 2019-02-28 | −7,512.61% | −6711.03 pp |
| Q1 2019 | 2018-11-30 | −3,158.14% | −808.99 pp |
| Q4 2018 | 2018-08-31 | −1,273.62% | — |
| Q3 2018 | 2018-05-31 | −2,440.44% | — |
| Q2 2018 | 2018-02-28 | −801.58% | — |
| Q1 2018 | 2017-11-30 | −2,349.15% | — |
| Q1 2016 | 2015-11-30 | −3,817.02% | — |
Lexaria Bioscience net profit margin trends
Over the last five fiscal years, Lexaria Bioscience's net profit margin decreased from −1,062.20% to −1,686.00%, a change of −623.80 percentage points. The latest reported quarter, Q2 2026, shows −7,249.89%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lexaria Bioscience source filings ↗